度普利尤单抗对特应性皮炎成人斑贴试验及过敏性接触性皮炎的影响不一
该回顾性研究评估度普利尤单抗对特应性皮炎(AD)患者斑贴试验结果及合并过敏性接触性皮炎(ACD)的影响。7例用药期间斑贴试验均至少1项阳性,共25种变应原反应达1+或更强;6例合并ACD者中仅3例ACD完全缓解。度普利尤单抗对斑贴试验及ACD缓解影响不一。
要点
- 度普利尤单抗治疗期间斑贴试验仍可显示阳性反应,但结果可能变化。
- 合并ACD的AD患者中,度普利尤单抗联合避敏仅部分患者ACD缓解。
- 临床需警惕度普利尤单抗治疗后ACD再暴露复发。
核心结论
- 度普利尤单抗对成人AD患者的斑贴试验结果及合并ACD的缓解影响不一。
研究设计与样本
- 回顾性研究,纳入接受度普利尤单抗治疗且行斑贴试验的AD患者7例,另分析合并ACD的AD患者6例。
主要发现
- 7例用药期间斑贴试验均至少1项阳性,共25种变应原反应达1+或更强,刺激反应少。
- 1例重复斑贴试验时多个既往阳性相关变应原未再出现阳性。
- 6例合并ACD者中,度普利尤单抗联合避敏使AD症状显著或完全缓解,但仅3例ACD缓解。
- 3例患者在再暴露于相关变应原时至少出现1次ACD发作。
临床怎么用
- 对AD患者应结合病史判断是否合并ACD,度普利尤单抗治疗期间斑贴试验仍可参考但需注意结果可变。
- 度普利尤单抗治疗后仍需坚持避敏,以防ACD复发。
局限性
- 回顾性、非对照研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous case reports and series suggested that dupilumab may be an effective treatment for allergic contact dermatitis (ACD). Little is known about the impact of dupilumab on patch test results and comorbid ACD in patients with atopic dermatitis (AD). OBJECTIVE: Determine the impact of dupilumab on patch testing results and improvement of ACD in patients with AD. METHODS: A retrospective study of patients with AD treated with dupilumab who underwent patch testing (n = 7) or had concomitant ACD (n = 6). RESULTS: In all, 7 patients with AD were patch tested while taking dupilumab; in all of these patients, at least 1 positive patch test reaction was observed, with a total of 25 different allergens having a reaction graded as 1+ or stronger and few irritant reactions. In 1 patient, multiple previously positive relevant patch test results were not duplicated upon repeat patch testing. In the 6 patients with AD and concomitant ACD, dupilumab and allergen avoidance resulted in substantial or complete resolution of AD signs and symptoms but resolution of ACD in only 3 patients. However, 3 patients had at least 1 flare of ACD upon re-exposure to relevant allergens. LIMITATIONS: Retrospective and uncontrolled study. CONCLUSIONS: Dupilumab had variable impact on patch testing results and resolution of comorbid ACD in adult patients with AD.
引用
- Stout M, Silverberg JI. Variable impact of dupilumab on patch testing results and allergic contact dermatitis in adults with atopic dermatitis. J Am Acad Dermatol. 2019. PMID: 30885752. doi:10.1016/j.jaad.2019.03.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。